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Highlights 
 Glycosimilarity is introduced to quantitatively address N-glycosylation differences  
 Practical examples of glycosimilarity assessment are given (innovator and biosimilar) 
 Quantitative differences between the N-glycan profiles are discussed  
 
Abstract 
The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics 
and their biosimilars plays essential roles in such major mechanisms of actions as antibody-
dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, anti-inflammatory 
functions and serum clearance. In addition, alteration in glycosylation may influence the safety 
and efficacy of the product. Glycosylation, therefore, is considered as one of the important 
critical quality attributes of glycoprotein biotherapeutics, and consequently for their biosimilar 
counterparts. Thus, the carbohydrate moieties of such biopharmaceuticals (both innovator and 
biosimilar products) should be closely scrutinized during all stages of the manufacturing process. 
In this paper we introduce a rapid, capillary gel electrophoresis based process to quantitatively 
assess the glycosylation aspect of biosimilarity (referred to as glycosimilarity) between the 
innovator and a biosimilar versions of etanercept (Enbrel® and Benepali®, respectively), based on 
their N-linked carbohydrate profiles. Differences in sialylated, core fucosylated, galactosylated 
and high mannose glycans were all quantified. Since the mechanism of action of etanercept is 
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TNFα binding, only mannosylation was deemed as critical quality attribute for glycosimilarity 
assessment due to its influence on serum half-life. 
 
Abbreviations: APTS: 8-aminopyrene-1,3,6-trisulfonic acid; CGE-LIF: capillary electrophoresis 
– laser induced fluorescence; CQA: critical quality attributes; ADCC: antibody-dependent cell-
mediated cytotoxicity; CDC: complement-dependent cytotoxicity; Fc: Fragment crystallizable; 
TNFα: tumor necrosis factor alpha; MOA: mode of action 
 
Keywords: glycosylation, biosimilarity, biologics, capillary gel electrophoresis 
 
1 Introduction 
Patent expiration on numerous biotherapeutics has created new opportunities for the 
pharmaceutical industry to develop biosimilars [1], i.e., versions of the innovative biological 
products, which are similar but not identical to the innovator product [2]. Most recombinant 
therapeutic proteins, e.g., monoclonal antibodies, fusion proteins with the Fc fragment of IgG, 
erythropoietin, etc., and subsequently their biosimilars are possessing various levels of N-
glycosylation. Even minor changes in their oligosaccharide structures (linkage, position, and site 
occupancy) can significantly influence their safety, efficacy, serum half-life and immunogenicity 
[3, 4]. Thus, information about the carbohydrate moieties of biosimilars is crucial to properly 
demonstrate similarity from the glycosylation point of view [5]. Regulatory agencies require 
comprehensive analysis of all critical quality attributes (CQA) to prove biosimilarity during the 
development and release of biosimilars, including their glycosylation [2, 6]. This special and 
important subset of biosimilarity is referred to as glycosimilarity [7]. 
 
Adequate determination of glycosimilarity requires proper evaluation of all important 
carbohydrate associated features like core fucosylation, galactosylation, sialylation and the 
presence of high mannose structures. The anticipated mechanism of action of a glycoprotein 
biopharmaceutical assumes appropriate glycosylation, which in turn represents carbohydrate 
related critical quality attributes [8]. For example, antibody-dependent cell-mediated cytotoxicity 
(ADCC) requires the absence of core fucosylation at the conserved Fc glycosylation of 
monoclonal antibodies or fusion proteins with Fc fragments. In the case of complement-
dependent cytotoxicity (CDC), antennary galactosylation is an important CQA feature [9]. 
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Mannosylation at the Fc region of monoclonal antibody therapeutics and IgG fusion proteins 
enhances clearance, so should be closely monitored during production and release [10]. 
 
Etanercept (Enbrel®) was developed to treat Rheumatoid Arthritis and other autoimmune 
diseases like Psoriasis, Ankylosing Spondylitis, etc. [11]. It is a highly glycosylated IgG Fc 
fusion protein that binds tumor necrosis factor alpha (TNFα), a cytokine involved in systemic 
inflammation [12]. Etanercept possesses three N-glycosylation sites on the TNFα receptor part 
(Asn149, Asn171, and Asn317) and one on the conserved N-linked site of the IgG Fc portion 
(Asn297). The two parts are connected with a heavily O-glycosylated (13 sites) linker [13]. Since 
TNFα binding represents the mechanism of action of etanercept, Fc function-associated sugar 
residues like sialylation, core fucosylation or terminal galactosylation are not of high 
significance from glycosimilarity point of view. Information about the mannosylation level of the 
product, on the other hand, is important from the perspective of serum half-life [14].  
 
Bioanalytical techniques such as nuclear magnetic resonance spectroscopy, mass spectrometry, 
slab gel electrophoresis and high-performance liquid chromatography, commonly used for the 
analysis of complex carbohydrates [15], are slow and/or offer less than adequate resolution. 
Capillary electrophoresis is an electric field driven high performance separation technique 
featuring high separation power and excellent detection limits for oligosaccharides [16]. In this 
paper we introduce this technique for comparative quantitative characterization of the N-
glycosylation and associated glycosimilarity assessment for an innovator biologics fusion protein 
(Enbrel®) and one of its biosimilars (Benepali®) using capillary gel electrophoresis with laser 
induced fluorescent detection. 
 
2 Materials and methods 
2.1 Chemicals and reagents 
The biopharmaceutical products of Enbrel® (innovator) and Benepali® (biosimilar) were kindly 
provided by the Medical School of University of Debrecen (Debrecen, Hungary). The Fast 
Glycan Sample Preparation and Analysis kit was from SCIEX (Brea, CA), the PNGase F enzyme 
from New England Biolabs (Ipswich, MA). The sodium cyanoborohydride (1 M, in THF) and all 
other chemicals were obtained from Sigma-Aldrich (St Louis, MO). 
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2.2 Sample preparation 
The Fast Glycan kit (SCIEX) was used for sample preparation and analysis including 
fluorophore labeling with 8-aminopyrene-1,3,6-trisulfonic acid (APTS), magnetic bead based 
sample purification and capillary electrophoresis separation. Briefly, 100 µgs of both the 
innovator and the biosimilar products first underwent PNGase F digestion to liberate their N-
glycans, followed by magnetic bead-mediated capture of the free oligosaccharides. This was 
followed by fluorescent labeling of the released carbohydrates with APTS, and another magnetic 
bead-mediated purification for excess labeling dye removal as reported before in detail [17]. The 
labeled glycans were then ready for CGE-LIF analysis, or were stored at -20oC until further 
processing.  
 
2.3 Separation and data analysis 
The PA 800 Plus Pharmaceutical Analysis System (SCIEX) used in all separation experiments 
was equipped with a solid state laser-based fluorescent detector (λex=488 nm/λem=520 nm). The 
separations were accomplished using either 20 cm (EZ-CE cartridge) or 50 cm effective length 
(50 μm I.D.) bare fused-silica capillary columns, filled with HR-NCHO gel buffer system 
(SCIEX). Reversed polarity separation mode was used in all analyses by applying 30 kV electric 
field strength either at 30°C or by the implementation of the temperature gradient of 15-55°C. 
The samples were injected by a three-stage injection protocol: 1) 3.0 psi for 5.0 sec water, 2) 2.0 
kV for 2.0 sec sample and 3) 1.0 kV for 1.0 sec bracketing standard (DP2 and DP15). The 32 
Karat software, version 10.1, (SCIEX) was employed for data acquisition and processing. 
Glycans were identified by their GU value from the built-in database of the software. Relative 
peak areas were used for quantitative comparison of the N-glycan profiles of the innovator 
product and its biosimilar counterpart. 
 
3 Results and discussion 
Capillary electrophoresis with laser-induced fluorescent detection (CGE-LIF) is a fast and 
efficient method to identify and quantitatively compare N-glycan profiles of biotherapeutics. In 
this work, we first optimized the separation temperature to obtain the highest resolution among 
the etanercept N-glycans, then quantitatively compared the released carbohydrates between the 
originator and the biosimilar products. 
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3.1 Separation temperature optimization 
As it has been previously reported, the electromigration properties of carbohydrates are 
activation energy dependent [18], thus first the separation temperature was optimized to obtain 
the highest resolution between the peaks of interest. One of the fastest way of separation 
temperature optimization in capillary electrophoresis is the application of a temperature gradient 
[19]. Figure 1 depicts the separation of the APTS labeled etanercept N-glycans using a 
temperature gradient from 15°C to 55°C. Based on the results, 30°C separation temperature 
seemed to be adequate to obtain the required resolution for all 18 carbohydrates of interest, 
especially between the A2 and Man5 glycans (peaks 7 and 8, respectively), which are important 
CQA features. Individual separation temperatures of 25°C, 30°C and 35°C were also evaluated 
using a 20 cm effective (30 cm total) length capillary tubing to validate the gradient findings of 
30°C optimum (data not shown). 
 
3.2 Comparative CGE-LIF analysis of the N-glycosylation of the innovator and biosimilar 
products  
Next, N-glycan profiles of the the innovator biologics, Enbrel®, and the biosimilar product, 
Benepali®, were comparatively analyzed by CGE-LIF at 30°C using 20 cm separation distance. 
The resulting electropherograms are shown in Figure 2. The lower and upper traces depict the 
separations of the APTS labeled N-linked oligosaccharides of the two products, respectively. As 
one can observe, the same peaks were detected in both instances, but with different peak 
distribution, thus, the different relative amounts were quantitated due to micro-heterogeneity 
observed. Quantitative assessment was obtained from the relative peak areas and discussed in 
detail in the next paragraph. 
 
3.3 Quantitative glycosimilarity assessment 
Quantitative peak distribution changes are visualized in Figure 3, where the bars represent the 
individual glycan structures shown in the X axis corresponding to the originator (dark) and the 
biosimilar (gray) products. Each bar denotes the average corrected peak areas of 6 runs. Table 1 
lists peak identities (numbers correspond to peaks in Figures 1), relative peak area percent values, 
similarity ratios and similarity percentages (tolerance %). The generally accepted ±20% 
tolerance window was applied for glycosimilarity assessment [7]. Only peaks with larger than 
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1% peak area (peaks 1, 2, 5-11, 13, 15-18) were evaluated in this study in respect to 
glycosimilarity. 
The peak areas of all di- and mono-sialo structures complying with the >1% relative peak area 
criteria (peaks 1, 2, 5, 6 and 9) were smaller in the biosimilar that of in the innovator product. 
While the di-sialo glycans (peaks 1 and 2) fall out of the 20% tolerance window (-30 and -35%, 
respectively), the significant mono-sialo products (peaks 6 and 9) were in the range (-16 and -
14%, respectively). Since anti-inflammatory characteristics of these products were no MOA 
importance, even with the average of ~33% difference in their abundance did not represent a 
CQA issue. Similarly, the higher representation of the afucosylated neutral glycans (peaks 7 and 
17) found in the biosimilar in comparison to the innovator drug, while well outside of the 
tolerance window (+63 and +130%, respectively), were not of CQA importance as the ADCC 
was not an MOA requirement for this product. The largest peak in both electropherograms was 
the core fucosylated biantennary glycan (FA2). This feature was represented in more than 36% in 
the innovator product than in the biosimilar, however, as CDC was not the MOA, it was not 
considered in the glycosimilarity assessment. Conversely, the abundance of highly galactosylated 
glycans (peaks 17 and 18), which were apparently much greater in the biosimilar than in the 
innovator (+130 and +124%, respectively), did not play a glycosimilarity role either. 
Interestingly, the peak area differences for the monogalactosylated glycans (peaks 15-16) were 
very similar and within the tolerance window (+7 and +10%, respectively). This was also true for 
the high mannose structures (peaks 8 and 11), where the difference between the innovator and 
biosimilar was below the tolerance window (-13 and +19%, respectively). Due to the fact that 
mannosylation on the Fc region of therapeutic IgG antibodies as well as Fc fragment containing 
fusion proteins, such as etanercept, affects the rate of serum clearance in humans, the presence (if 
any) and the extent of high mannose glycans were deemed as an important critical quality 
attribute of glycosimilarity prospective.  
 
4 Conclusions 
N-glycosylation plays an essential role in the mechanism of action for most glycoprotein 
biotherapeutics, thus represents an important CQA subset for biosimilarity. Comprehensive N-
glycosylation characterization by capillary gel electrophoresis with laser-induced fluorescent 
detection (CGE-LIF) provided rapid, high-resolution separations with the option of quantitative 
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assessment of the carbohydrates of interest from glycosimilarity point of view. Identification and 
quantitative comparison of the relative peak areas between the N-glycan profiles of the innovator 
product (Enbrel®) and its biosimilar counterpart (Benepali®) were used as a model system to 
demonstrate glycosimilarity assessment analysis. Albeit, significant quantitative differences were 
found in sialylated, core-fucosylated and galactosylated structures between the innovator and the 
biosimilar, since ADCC and CDC functions were not critical to the mechanisms of action of 
these products, this subset of the data was not considered in glycosimilarity assessment. 
Mannosylation, on the other hand, plays an important role in serum clearance, so quantification 
based similarity evaluation of the high mannose structures represented an important CQA, with 
which, based on our results, this particular biosimilar version of etanercept (Benepali®) complied. 
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Figures and tables 
 
Figure 1. Temperature gradient capillary gel electrophoresis of released and APTS labeled 
etanercept N-glycans. Structures corresponding to the peak numbers are delineated in Table 1. 
DP2 (maltose), DP3 (maltotriose) and DP15 (maltopentadecaose) are bracketing and internal 
standards. Conditions: 50 cm effective (60 cm total, 50 µm ID) fused silica capillary column 
filled with HR-NCHO gel buffer. Applied electric field: 500 V/cm. Separation temperature 
(dashed line): 0-14 min: 15oC isotherm, 14-18 min: linear increase from 15 to 55°C, 18-22 min: 
55°C, isotherm. Injection sequence: 3.0 psi/5.0 sec water; 2.0 kV/2.0 sec sample and 1.0 kV/1.0 
sec bracketing standard. 
 
Figure 2. CGE-LIF analysis of PNGase F-released and APTS labeled asparagine-linked 
oligosaccharides from Enbrel® (innovator, lower trace) and Benepali® (biosimilar, upper trace). 
Separation conditions were the same as in Figure 1 except: 20 cm effective (30 cm total, 50 µm 
ID) fused silica capillary column filled with HR-NCHO gel buffer. Applied electric field: 1000 
V/cm; Separation temperature: 30°C (isotherm). The upper X-axis depicts the degree of 
polymerization values (DP) of the maltooligosaccharide ladder to help structural elucidation.  
 
Figure 3. Quantitative N-glycosylation comparison of Enbrel® and Benepali® at the individual 
carbohydrate level.  
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Table1. Quantitative N-glycosylation similarity analysis of the innovator (Enbrel®) and biosimi-
lar (Benepali®) products. Features with less than 1% peak area (gray lines) were not evaluated in 
this study in respect to glycosimilarity. 
Peak Abbreviation 
Glycan comp. 
letter 
Stucture 
Peak Area% Similarity 
ratio 
Tolarence 
(%) Enbrel Benepali 
1 A2G2S2 H5N4A2 
  
3.53 2.45 0.70 -30.44 
2 FA2G2S2 H5N4A2F1 
  
5.04 3.27 0.65 -35.02 
3 A2G(6)1S1 H4N4A1 
  
0.11 0.34 3.09 209.09 
4 FA2(6)G1S1 H4N4A1F1 
  
0.35 0.28 0.80 -20.00 
5 FA2(3)G1S1 H4N4A1F1 
  
1.86 1.01 0.54 -45.68 
6 A2G2S1 H5N4A1 
  
14.74 12.28 0.83 -16.65 
7 A2 H3N4 
  
1.61 2.64 1.64 63.81 
8 M5 H5N2 
  
2.49 2.16 0.87 -13.41 
9 FA2G2S1 H5N4A1F1 
  
15.09 12.96 0.86 -14.15 
10 FA2 H3N4F1 
  
24.06 15.24 0.63 -36.69 
11 M6 H6N2 
  
0.88 1.05 1.19 19.32 
12 A2(3)G1 H4N4 
  
0.51 0.46 0.90 -9.80 
13 FA2B H3N3F1 
  
0.44 1.13 2.59 159.18 
14 FA3  H3N5F1 
  
0.35 0.49 1.40 40.00 
15 FA2(6)G1 H4N4F1 
  
13.33 14.29 1.07 7.20 
16 FA2(3)G1 H4N4F1 
  
4.95 5.49 1.11 10.85 
17 A2G2 H5N4 
  
4.11 9.47 2.31 130.69 
18 FA2G2 H5N4F1 
  
6.63 14.91 2.25 124.94 
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